Return to homepagePandemic Pact

Development of chemical synthesis vaccine against SARS-CoV-2

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    RIKEN

  • Principal Investigator

    Kenichi Masuda

  • Research Location

    Japan

  • Lead Research Institution

    Vaccine Innovation Laboratory, RIKEN Baton Zone Program

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Our team has developed a new technology "mMAP" (mutation compatible multiple antigen peptides) which could help to overcome the problems of virus mutation and antibody dependent enhancement. A COVID-19 vaccine using this technology is currently under development.